Main content

    Gastric Cancer

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: A Randomized, Phase II, Placebo-Controlled Study Of GDC-0068, An Inhibitor To AKT, In Combination With Fluoropyrimidine Plus Oxaliplatin In Patients With Locally Advanced Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma
    Decscription: To evaluate the efficacy of GDC-0068 combined with mFOLFOX-6 compared with placebo combined with mFOLFOX-6
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed, inoperable, locally advanced or metastatic gastric or GEJ adenocarcinoma, who have received no prior treatment for advanced or metastatic disease
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: about Study Genetech GO28341

    • updated January 2014

    Back to top